Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations

v3.23.2
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Operating expenses:        
Research and development (including related party purchases of $786 and $583 for the three months ended June 30, 2023 and 2022, respectively, $914 and $1,227 for the six months ended June 30, 2023 and 2022, respectively.) $ 88,849 $ 74,205 $ 164,367 $ 146,276
Selling, general and administrative (including related party purchases of $139 and $128 for the three months ended June 30, 2023 and 2022, respectively, $163 and $289 for the six months ended June 30, 2023 and 2022, respectively.) 27,120 25,177 51,318 47,449
Total operating expenses 115,969 99,382 215,685 193,725
Loss from operations (115,969) (99,382) (215,685) (193,725)
Interest and other income, net 10,683 2,554 19,083 3,311
Income from equity method investment 0 4,581 0 19,039
Gain (Loss) from change in fair value of warrants and earnout shares (180,737) 42,698 (202,780) 59,512
Total other income (loss), net (170,054) 49,833 (183,697) 81,862
Loss before income taxes (286,023) (49,549) (399,382) (111,863)
Income tax expense 56 25 90 30
Net loss $ (286,079) $ (49,574) $ (399,472) $ (111,893)
Net loss per share, basic (in dollars per share) $ (0.45) $ (0.09) $ (0.64) $ (0.19)
Net loss per share, diluted (in dollars per share) $ (0.45) $ (0.09) $ (0.64) $ (0.19)
Weighted-average common stock outstanding, basic (in shares) 636,679,165 581,265,924 621,018,919 580,184,274
Weighted-average common stock outstanding, diluted (in shares) 636,679,165 581,265,924 621,018,919 580,184,274